Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Phase 3 Cancer Trials

Research area

Phase 3 Lung Cancer trials

The lung cancer studies listed here are all in Phase 3, including combined Phase 2/3. Whether a particular study might suit you is something Phase 3 Cancer Trials can help you find out.

Updated

Call (888) 306-7888
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Phase 3 lung cancer studies in numbers

Phase 3 lung cancer studies recruiting in the U.S.
88
states with a study site
51

Source: ClinicalTrials.gov. Data processed .

Find Phase 3 lung cancer studies by state

These states have the most studies recruiting right now.

Phase 3 lung cancer studies recruiting now

As of November 18, 2026, 88 Phase 3 lung cancer studies are recruiting participants in the United States, according to ClinicalTrials.gov. This site lists only studies that are in Phase 3, including combined Phase 2/3, as each study is coded in the registry. This is what they have in common.

What they test

  • medications76
  • biologics such as vaccines or antibodies23
  • other approaches16
  • procedures11
  • devices4

A study can test more than one.

Main purpose

  • treating a condition85
  • prevention1
  • screening1
  • supportive care1

Phase

  • Phase 2/312
  • Phase 376

Who runs them

  • industry72
  • university, hospital or other11
  • government5

Who they enroll

  • adults (18 to 64)87
  • older adults (65 and over)87

These counts come from each study's public record and change as studies open and close. Browse every location to see what is recruiting near you.

Source: ClinicalTrials.gov. Data processed . Each bar shows a count as a share of all 88 studies.

Recently updated Phase 3 lung cancer studies

The 6 studies whose public records changed most recently, with some of the places each is recruiting. Select a study to read its full record on ClinicalTrials.gov.

  1. Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    ‘Aiea, HI · ‘Ewa Beach, HI · Aberdeen, MD · and 223 more U.S. locations
    Registry record
    NCT06498635 · updated
  2. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Summit Therapeutics
    Recruiting in
    Abilene, TX · Alameda, CA · Anaheim, CA · and 86 more U.S. locations
    Registry record
    NCT06767514 · updated
  3. Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Daiichi Sankyo
    Recruiting in
    Anchorage, AK · Atlanta, GA · Bay Pines, FL · and 22 more U.S. locations
    Registry record
    NCT06899126 · updated
  4. Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Boehringer Ingelheim
    Recruiting in
    Abilene, TX · Amarillo, TX · Atlanta, GA · and 17 more U.S. locations
    Registry record
    NCT07195695 · updated
  5. Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy and With Tarlatamab, Alone or With Chemotherapy, in Adult Participants With Extensive-Stage Small Cell Lung Cancer

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    Pfizer
    Recruiting in
    Allen, TX · Arlington, TX · Beaumont, TX · and 41 more U.S. locations
    Registry record
    NCT07226999 · updated
  6. Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Ames, IA · Anaconda, MT · Anaheim, CA · and 124 more U.S. locations
    Registry record
    NCT07388524 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in the United States on ClinicalTrials.gov.

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and some of the places it is recruiting) exactly as registered. Nothing in a record is reworded. This site lists only studies that are in Phase 3, including combined Phase 2/3, as each study is coded in the registry.

Phase 3 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

What Phase 3 lung cancer studies look at

The lung cancer studies you see here are in Phase 3, including combined Phase 2/3. No two of them ask the same thing. Each is built around a single question, and that question shapes the tasks set for you. Your part can look quite different between studies.

Every product under study is investigational. Its risks, and how well it works, are things researchers are still finding out. That open question is why the study is being run at all.

Who may be able to take part

Who can join depends on the trial. Each Phase 3 lung cancer trial sets requirements of its own. A study might look at how old you are and at your past health. It might also look at what you currently take, or at how lung cancer affects you. Some also enroll people who do not have lung cancer.

Sorting out eligibility is not something you have to do alone. It is checked at screening, when the study team goes through it with you in person. See how eligibility and screening work.

What taking part usually involves

  1. A first conversation

    First comes a conversation. You hear a broad outline of the study from a coordinator, who also answers whatever you ask. Nothing further takes place until then.

  2. Informed consent

    Next, the study team hands you a written document. It sets out everything in full and covers the risks known so far. You choose whether to say yes.

  3. Screening

    Screening comes next. You answer health questions and have some tests. The results show whether this Phase 3 lung cancer trial suits you. Some people are screened and do not end up joining.

  4. Study visits

    Joining a Phase 3 lung cancer trial means coming to planned visits. At each one, the study team checks on your health. Leaving is always your choice, and you can make it at any point.

Questions about Phase 3 lung cancer studies

Do I need a diagnosis to join a study about lung cancer?

Not always. It comes down to the individual trial. One Phase 3 lung cancer trial may ask for a confirmed diagnosis. Another may assess you itself at screening. Which of these applies to you is something the study team will explain.

Would I have to change the care I receive now?

It depends on the Phase 3 lung cancer study. Some let your current care carry on, and some do not. Please leave your care as it is and make no changes by yourself. That is a conversation you will have with the study's doctor. Your own doctor can help you think it through before you decide.

Is there a cost to take part?

The study side of a Phase 3 lung cancer trial generally costs you nothing as a participant. That covers its visits, its tests, and the medication the study provides. Read more about costs.

Ask about Phase 3 lung cancer studies

Tell us a little about yourself, and a coordinator will get in touch. Asking places you under no obligation.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Independent information

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 306-7888

or send a short form

How should we reach you?

Call